Sotera Health (SHC) Scheduled to Post Quarterly Earnings on Tuesday

Sotera Health (NASDAQ:SHC - Get Free Report) will announce its earnings results before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of $0.17 per share for the quarter. Sotera Health has set its FY24 guidance at $0.67-$0.75 EPS and its FY 2024 guidance at 0.670-0.750 EPS.Persons interested in listening to the company's earnings conference call can do so using this link.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its earnings results on Monday, August 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.15 by $0.04. The business had revenue of $277.00 million during the quarter, compared to the consensus estimate of $266.45 million. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. Sotera Health's revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.19 earnings per share. On average, analysts expect Sotera Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sotera Health Trading Up 0.6 %

SHC traded up $0.09 during trading on Tuesday, reaching $15.92. The company had a trading volume of 664,899 shares, compared to its average volume of 1,310,400. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.44. The company has a market cap of $4.51 billion, a price-to-earnings ratio of 113.71 and a beta of 2.07. The firm's 50-day simple moving average is $15.92 and its 200 day simple moving average is $13.50.

Insider Buying and Selling at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 55.12% of the company's stock.

Wall Street Analysts Forecast Growth

SHC has been the topic of a number of recent analyst reports. Royal Bank of Canada restated an "outperform" rating and set a $17.00 price target on shares of Sotera Health in a report on Tuesday, August 6th. Barclays boosted their target price on shares of Sotera Health from $14.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $15.70.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.